GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » PEG Ratio

Sangamo Therapeutics (Sangamo Therapeutics) PEG Ratio

: 0.00 (As of Today)
View and export this data going back to 2000. Start your Free Trial
PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Sangamo Therapeutics's PE Ratio without NRI is 0.00. Sangamo Therapeutics's 5-Year EBITDA growth rate is 1.20%. Therefore, Sangamo Therapeutics's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Sangamo Therapeutics's PEG Ratio or its related term are showing as below:



SGMO's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.485
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Sangamo Therapeutics PEG Ratio Historical Data

The historical data trend for Sangamo Therapeutics's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sangamo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PEG Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Sangamo Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics PEG Ratio Distribution

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's PEG Ratio falls into.



Sangamo Therapeutics PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Sangamo Therapeutics's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/1.20
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Sangamo Therapeutics  (NAS:SGMO) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Sangamo Therapeutics PEG Ratio Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005

Sangamo Therapeutics (Sangamo Therapeutics) Headlines

From GuruFocus